Rocket Pharmaceuticals (RCKT) Liabilities and Shareholders Equity (2014 - 2026)

Rocket Pharmaceuticals has disclosed Liabilities and Shareholders Equity across 13 years of filings, most recently posting $285.4 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $285.4 million, down 39.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (down 23.6% YoY), and the FY2025 annual result was $330.4 million, down 37.38% from the prior year.
• Liabilities and Shareholders Equity came in at $285.4 million for Q1 2026 at Rocket Pharmaceuticals, down from $330.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $598.8 million in Q3 2023 to a low of $285.4 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $460.2 million (2022), against an average of $455.6 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 43.5% in 2023 and sank 39.41% in 2026, its largest moves.
• Rocket Pharmaceuticals' Liabilities and Shareholders Equity stood at $551.8 million in 2022, then grew by 2.63% to $566.3 million in 2023, then dropped by 6.82% to $527.7 million in 2024, then slumped by 37.38% to $330.4 million in 2025, then decreased by 13.63% to $285.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $285.4 million (Q1 2026), $330.4 million (Q4 2025), and $368.0 million (Q3 2025), per Business Quant data.